Apolipoprotein levels in non-insulin-dependent diabetes mellitus with clinical macroangiopathy.
To elucidate the changes of serum apolipoproteins as possible atherogenic factors in non-insulin-dependent diabetes mellitus (NIDDM), comparison was made between 47 NIDDM patients with clinical macroangiopathy (coronary heart disease and/or cerebral infarction) and 47 NIDDM patients without clinical macroangiopathy individually matched for age, sex, body mass index, glycemic control, mode of therapy, and blood pressure. Serum total cholesterol (223 +/- 63 mg/dl, mean +/- SD) and triglyceride (160 +/- 72 mg/dl) levels in NIDDM with clinical macroangiopathy were significantly higher than those (198 +/- 44 and 126 +/- 78 mg/dl) in control NIDDM. Apolipoprotein AII (apo AII) (28.8 +/- 6.9 mg/dl) in NIDDM with clinical macroangiopathy was significantly lower than that (31.4 +/- 5.5 mg/dl) in control NIDDM, and apo B (147 +/- 48 mg/dl) and apo CIII (13.1 +/- 5.9 mg/dl) in NIDDM with clinical macroangiopathy was significantly higher than that (113 +/- 35 and 10.8 +/- 4.7 mg/dl) in control NIDDM, respectively. There were no significant differences in apo AI, CII, and E levels. The ratio of HDL cholesterol to apo AI (0.36 +/- 0.08) and total cholesterol to apo B (1.6 +/- 0.3) in NIDDM with clinical macroangiopathy was significantly lower than that (0.40 +/- 0.09 and 1.8 +/- 0.4) in control NIDDM. These results suggest that abnormality of lipid metabolism is more significant in NIDDM with clinical macroangiopathy than in NIDDM without clinical macroangiopathy, and is more pronounced in women than in men.